Press releaseGlobe Newswire
Autolus Therapeutics
AUTL · NASDAQ
$1.66+$0.07 (+4.40%)TodayMarket closed ·
Prev close $1.59
Latest news
- Press releaseGlobe Newswire
Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
- Press releaseGlobe Newswire
Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
- NewsAvi Kapoor
CNH Industrial Posts Upbeat Q2 Earnings, Joins Autolus Therapeutics, Bowhead Specialty Holdings And Other Big Stocks Moving Higher On Monday
- Press releaseGlobe Newswire
Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors
- NewsAvi Kapoor
Toyo Posts Upbeat Q1 Earnings, Joins Brady, Dominion Energy And Other Big Stocks Moving Higher On Monday
- News
Autolus Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript
- News
Earnings Scheduled For May 14, 2026
- Press releaseGlobe Newswire
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
- Press releaseGlobe Newswire
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
- News
Earnings Scheduled For March 27, 2026
- Press releaseGlobe Newswire
Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
- Press releaseGlobe Newswire
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
- Press releaseGlobe Newswire
Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026
- Press releaseBusiness Wire
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform
- NewsAvi Kapoor
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- NewsAvi Kapoor
DigitalBridge Group, Eightco Holdings, Palisade Bio And Other Big Stocks Moving Higher On Monday
- Press releasePRNewswire
Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
- NewsVandana Singh
Why Is Autolus Therapeutics Stock Trading Higher On Tuesday?
- NewsAvi Kapoor
Abercrombie & Fitch, Titan Machinery, Zoom Communications, Woodward And Other Big Stocks Moving Higher On Tuesday
- Press releaseGlobe Newswire
Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
- News
Earnings Scheduled For November 12, 2025
- News
A Look at Autolus Therapeutics's Upcoming Earnings Report
- Press releasePRNewswire
Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
- Press releaseGlobe Newswire
Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
- NewsVandana Singh
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
- Press releasePRNewswire
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
- News
What 4 Analyst Ratings Have To Say About Autolus Therapeutics
- Press releaseGlobe Newswire
Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
- News
Earnings Scheduled For May 8, 2025
- Press releaseGlobe Newswire
Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event
- Press releaseBusiness Wire
Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition
- Press releaseGlobe Newswire
Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
- NewsAvi Kapoor
This InterContinental Hotels Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
- Press releaseGlobe Newswire
Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
- NewsAvi Kapoor
Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
- Press releaseGlobe Newswire
Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.